DESTINY-Breast11, DESTINY-Breast05 & What Comes Next – Dr. Neil Iyengar & Dr. Komal Jhaveri

Recorded with Drs. Neil Iyengar and Komal Jhaveri, this in-depth discussion breaks down the most practice-shifting data in early-stage HER2-positive breast cancer — from neoadjuvant to adjuvant decision-making.

The conversation explores DESTINY-Breast11 and its unprecedented pathologic complete response rates with sequential T-DXd followed by THP, including an 83% pCR in hormone receptor–negative disease. The panel also examines safety, ILD risk, anthracycline-free strategies, and how these results may reshape neoadjuvant standards.

The discussion then moves to DESTINY-Breast05, where T-DXd demonstrated superiority over T-DM1 in the residual disease setting, with a hazard ratio of 0.5 for invasive disease-free survival — raising critical questions about patient selection, CNS recurrence, and curative intent strategies.

A must-watch episode for clinicians navigating the rapidly evolving HER2-positive landscape.